VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase following the completion of its collaboration with OmniAb. The company now plans to engineer the final candidate using its proprietary antibody-engineering, linker and conjugation technologies and to conduct in vitro and in vivo preclinical studies. This progression marks a significant step in VERAXA's efforts to develop next-generation cancer therapies.
VXA-222 employs an "AND-gate" design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells while reducing off-target effects. This innovative approach could lead to more precise and effective treatments for patients with difficult-to-treat cancers. The company continues to develop a broader oncology pipeline spanning ADCs, T-cell engagers and other engineered antibody formats.
In addition to advancing VXA-222, VERAXA has filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms and related payload, click-chemistry and conjugation technologies. These filings add to an intellectual-property portfolio that includes more than 50 granted patents across 26 families in 14 countries. The expansion of VERAXA's patent estate underscores its commitment to protecting its innovative technologies and could enhance its competitive position in the rapidly evolving field of antibody-based therapeutics.
The completion of the OmniAb collaboration and the subsequent advancement of VXA-222 highlight VERAXA's ability to translate scientific discoveries into development-stage programs. For investors, this progress may signal the company's potential to bring novel therapies to market. For the biotech industry, it represents a continued push toward more sophisticated ADC designs that could improve treatment outcomes. For patients, it offers hope for new options in cancer care.
VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. For regular updates about VERAXA Biotech, visit www.VERAXA.com.
The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. For a full view of the article, visit https://ibn.fm/S3tyP.
InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. InvestorWire provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of social media followers. These services help companies reach a wide audience of investors, influencers, consumers, journalists and the general public.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
